Table 1.
Combined Cases
| Reference | Case Number | Median Age (Range,years) | Sex | HIV + | Epstein- Barr Virus encoded RNA | CD4+ Cell Count at Diagnosis (median, cells/μL) | HIV Viral load (copies/mL) | HIV/AIDS Therapy | Prior AIDS Diagnosis | Lymphoma Stage | Chemotherapy regimen | Response | FU (median,months) | Comments | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Index Case | 1 | 57 | M | Yes | (+) | 1344 | <50 | EFV/ FTC/ TDF | No | IIIA | R-EPOCH | (CR) | 12+ | Elevated HHV-8 viral load at diagnosis- not detectable at last FU. | |
| Guillet et al.13 | 2–18 | 41 (39–53) |
16- M 1- F |
Yes | NR | 204 (103–377) |
17- NR | 11- HAART 6- NR |
9- Yes 8- NR |
7- Stage IV 10- NR |
CHOP + HDMTX,ASCT |
7(CR) 10(NR) |
120 + | 7/17 patients achieved remission. None of these patients had reccurent lymphoma at time of follow up. | |
| Chadburn et al.7 | 19–26 | 40 (27–51) |
M | Yes | 7(+) 1(−) |
3- 188 (43–714) 5- NR |
2- UD 6- NR |
1- pre-HAART 4- None 3- NR |
2- Yes 1- No 5- NR |
1- III 2- IIIB 2- IV 3- NR |
6-Chemotherapy 1- N/A 1- NR |
3(CR) 1(PD) 4(NR) |
11 +, 25+, and
44+ 5 |
Patient with PD died 5 months following
diagnosis. Individual chemotherapy regimens NR. |
|
| Carbone et al.5 | 27 28 |
75 52 |
M M |
No No |
(−) (+) |
470 501 |
N/A N/A |
N/A N/A |
N/A N/A |
IVB IIIA |
CHOP CEOP |
(SD) 3(PD) |
2+ 8+ |
||
| Carbone et al.4 | 29 30 31 |
39 24 41 |
M F M |
Yes Yes Yes |
(−) (+) (+) |
20 282 104 |
NR 125.155 <50 |
NR NR NR |
Yes No Yes |
IVB IVB IVB |
CHOPLD VCR-BLM CHOPLD |
(PD) (PD) (PD) |
15 25 45 |
All three patients died. | |
| Pan et al.8 | 32–40 | 44 (26–77) |
M | Yes | 8(+) 11(−) |
3- 160 (7–443) 6- NR |
NR | NR | 3- Yes 6- No |
NR | NR | 5(NR) 4(PR) or (CR) |
16 days 6+, 15+, and 33+ |
Cause of death NR. Outcomes were reported for four of the nine patients. |
|
| El-Ayass et al.30 | 41 | 48 | M | Yes | NR | 19 | 431,855 | HAART | Yes | NR | EPOCH | (CR) | 14+ | Individual HAART therapy NR. | |
| Deloose et al.29 | 42–50 | 41 (35–54) |
M | Yes | 8(+) 1(−) |
NR | NR | NR | NR | 8- IV 1- IIE |
NR | (NR) | NR | ||
| Costes et al.27 | 51 52 |
44 41 |
M M |
Yes Yes |
(+) (+) |
<50 NR |
NR NR |
HAART HAART |
Yes Yes |
NR NR |
PCT | (CR) (CR) |
8+ 8+ |
Individual HAART therapy
NR. Specific chemo regimen not reported for either patient. |
|
| Shah et al.49 | 53 | 33 | M | Yes | (+) | 60 | 184,000 | HAART | Yes | NR | R-EPOCH+, IT-MTX, ESHAP ×6 | (CR) | 6+ | Individual HAART therapy
NR. Patient showed CR after four cycles of R- EPOCH. |
|
| Hasegawa et al.34 | 54 | 50 | M | Yes | (−) | 0.044 | 73,000 | HAART | Yes | Yes | CHOP | (CR) | NR | Individual HAART therapy NR. FU data NR; lymphoma lesions disappeared after initiation of HAART and CHOP. |
|
| Oksenhendl er et al.44 | 55 56 57 58 |
NR | NR | Yes | (−) (−) (NR) (−) |
260 686 1126 114 |
334,000 <500 362,000 <50 |
D4T-3TC-RTV AZT-3TC-IDV NR ABC-DDL-RTV-SQV |
No No No Yes |
NR | EDX-VP16 None ACVBP CHOPLD |
(PR) (PD) (CR) (PD) |
5 3 weeks 25+ 7 weeks |
Cause of death for cases 55, 56, and 58 are
NR. Case 57 remains in follow-up. |
|
| Zhang et al.53 | 59 | 46 | M | Yes | (+) | 88 | >100,000 | HAART | Yes | NR | R-C | (PD) | 2 weeks | Patient continued to decline
despite antiretroviral and chemo intervention. Death due to sepsis, worsening acidosis, hepatorenal failure, and hypotension. |
|
| Kim et al.38 | 60 61 62 |
55 42 42 |
M | Yes | (−) (+) (−) |
NR | NR | HAART | NR | NR | NR | (CR) (CR) (NR) |
13+ 25+ NR |
Individual HAART therapy NR. NED at follow-up. | |
| Engels et al.31 | 63–65 | 48 (41–48) |
M | Yes | 2(+) 1(−) |
94 2- NR |
NR | NR | 1-Yes 2-NR |
NR | NR | (NR) | NR | Overall survival or time to progression data NR. | |
| Andrews et al.21 | 66 | 46 | M | Yes | (−) | 159 | 511,000 | HAART | Yes | NR | 1. R-CHOP, IT-MTX, ESHAP
×1; 2. EPOCH, HDMTX ×3 |
(CR) | NR | Individual HAART therapy
NR. Patient switched to second regimen after being diagnosed with CNS disease. Patient continues to experience left sided numbness and facial nerve palsy |
|
| Huang et al.36 | 67 | 49 | M | Yes | (−) | NR | NR | HAART | No | NR | ICE + ASCT ×2 | (CR) | 2+ | Individual HAART therapy NR. | |
| Crane et al.28 | 68 | 59 | M | Yes | (+) | 526 | 93 | HAART | No | NR | None | (PD) | 2 | Patient performance status declined after and he was transferred to comfort care. | |
| Ferry et al.32 | 69 | 59 | M | Yes | (−) | NR | NR | HAART | No | NR | NR | (NR) | 8 days | Individual HAART therapy
NR. Death due to a combination of hypotension, acute renal failure, and metabolic acidosis. |
|
| Navarro et al.42 | 70 | 37 | M | Yes | (+) | 120 | NR | AZT | Yes | IVB | CHOP ×3 | (NR) | 3 | Death due to bilateral pneumonia. | |
| Beaty et al.11 | 71 | 32 | M | Yes | (+) | NR | NR | NR | No | NR | Surgical Resection | (CR) | 5 | NED at last follow-up. | |
| Buske et al.24 | 72 | 35 | M | Yes | (+) | NR | NR | NR | NR | NR | DOX | (PD) | 4 | Death due to septic shock four months after completing chemotherapy. | |
| Aboulafia et al.20 | 73 | 39 | M | Yes | (+) | 30 | 90,000 | 1. ART, 3TC 2.HAART |
Yes | IE | R-CHOP | (NR) | 1 week | Death due to fibril pneumonia. | |
| Giessen et al.33 | 74 | 38 | M | Yes | (+) | 390 | 19,000 | NVP, 3TC, ABC | No | NR | CHOP ×6 | (CR) | NR | FU data NR. | |
| Henao-Martinez et al.35 | 75 | 45 | M | Yes | (+) | 173 | 32,783 | TDF, FTC, RTV, ATV | Yes | NR | EPOCH | (CR) | 12+ | ||
| Pielasinski et al.47 | 76 | 33 | M | Yes | (+) | 288 | 1,078,000 | HAART | No | NR | CHOP | (CR) | 20+ | Individual HAART therapy NR. | |
| Meng-Feng et al.47 | 77 | 31 | M | Yes | (+) | 18 | <200 | NR | Yes | NR | VCR-BLM | (NR) | NR | Death 44 days after diagnosis. | |
| Verma et al.47 | 78 | 38 | F | No | (−) | NR | NR | NR | NR | NR | Surgical resection | (NR) | NR | ||
| Colom et al.47 | 79 | 51 | M | Yes | (+) | NR | NR | NR | NR | NR | NR | (NR) | NR | ||
| Katano et al.9 | 80 | 30 | M | Yes | (+) | 50 | NR | NR | Yes | NR | CV | (PR) or (CR) | NR | Death due to MCD and hemorrhage. | |
| Pantanowitz et al.45 | 81 | 40 | M | Yes | (+) | 300 | 86 | HAART | No | NR | CHOP | (CR) | 39+ | Patient continues to undergo HAART therapy, specific regimen NR. CD4 count remains >300 cells/mm^3. | |
| Mylona et al.54 | 82 | 39 | M | Yes | (NR) | 685 | <50 | TDF, DDL, LPV, RTV | Yes | NR | 1. EPOCH ×6 2. ESHAP ×2 |
(PD) | 24 | Individual HAART therapy NR. Death due to massive haemoptysis. | |
| Morand et al.40 | 83 | 40 | M | Yes | (+) | 10 | NR | NR | Yes | Yes | NR | (PD) | 2 weeks | Death due to infectious complications during chemotherapy. | |
ABC, abacavir; ddl, didanosine; ABVp, doxorubicin, bleomycin, etoposide; ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone; ASCT, autologous stem cell transplantation; AZT, zidovudine; CDE, cyclophosphamide, doxorubicin, etopside; CEOP, cyclophosphamide, epidoxorubicin, vincristine, prednisone; CHVp, cyclophosphamide, doxorubicin, etoposide; CHVp-M, cyclophosphamide, doxorubicin, etoposide, high-dose methotrexate; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CHOPLD, cyclophosphamide, doxorubicin, vincristine, predmustine (CHOP) 50% of dose; CHOP-M, cyclophosphamide, doxorubicin, vincristine, prednisone, high-dose methotrexate; CNS, central nervous system; CR, Complete Response; CV, Cyclophosphamide; CVp, cyclophosphamide, etoposide; d4T, stavudine; DOX, doxorubicin Dx, Diagnosis; EFV, Efavirenz; ESHAP, etoposide, cisplatin, high-dose methotrexate; F, Female; FTC, Emtricitabine; FU, Follow Up; HAART, highly active antiretroviral therapy; ICE, ifosfamide, carboplatin, etopside; IDV, indinavir; IT-MTX, intrathecal methotrexate; KS, Kaposi’s Sarcoma; LPV, lopinavir; M, Male; MCD, Multicentric Castleman’s Disease; N/A, Not applicable; HDMTX, High-dose methotrexate; NED, No Evidence of Disease; NHL; non-hodgkins lymphoma; NR, No Reported; NVP, Nevirapine; PCT, Polychemotherapy; PD, Progressive Disease; PR, partial response; R-C, rituximab, cyclophosphamide; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RTV, ritonavir; SD, stable disease; SQV, saquinavir; Tx, treatment; VCR-BLM, vincristine, bleomycin; TDF, Tenofovir, vinblastine; 3TC, lamivudine;